×
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
NASDAQ:HSTO

Histogen Stock Forecast, Price & News

$2.33
+0.07 (+3.10%)
(As of 06/29/2022 04:00 PM ET)
Add
Compare
Today's Range
$2.10
$2.36
50-Day Range
$2.15
$49.80
52-Week Range
$2.06
$22.60
Volume
47,629 shs
Average Volume
107,139 shs
Market Capitalization
$5.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00
30 days | 90 days | 365 days | Advanced Chart

Receive HSTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Histogen and its competitors with MarketBeat's FREE daily newsletter.

HSTO Stock Forecast (MarketRank)

Overall MarketRank

1.89 out of 5 stars

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -
Histogen logo

About Histogen (NASDAQ:HSTO)

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.

HSTO Stock News Headlines

Histogen Announces 1-for-20 Reverse Stock Split
Form DEFA14A Histogen Inc. - StreetInsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HSTO
Fax
N/A
Employees
22
Year Founded
N/A

Company Calendar

Last Earnings
11/10/2021
Today
6/29/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$30.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+1,187.6%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Net Income
$-14.95 million
Net Margins
-260.63%
Pretax Margin
-262.05%

Debt

Sales & Book Value

Annual Sales
$1.03 million
Book Value
$9.67 per share

Miscellaneous

Free Float
2,242,000
Market Cap
$5.82 million
Optionable
Not Optionable
Beta
0.96














Histogen Frequently Asked Questions

Should I buy or sell Histogen stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Histogen in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Histogen stock.
View analyst ratings for Histogen
or view top-rated stocks.

What is Histogen's stock price forecast for 2022?

1 brokerages have issued 1-year price objectives for Histogen's stock. Their HSTO stock forecasts range from $30.00 to $30.00. On average, they expect Histogen's stock price to reach $30.00 in the next year. This suggests a possible upside of 1,187.6% from the stock's current price.
View analysts' price targets for Histogen
or view top-rated stocks among Wall Street analysts.

How has Histogen's stock price performed in 2022?

Histogen's stock was trading at $6.6540 at the beginning of 2022. Since then, HSTO stock has decreased by 65.0% and is now trading at $2.33.
View the best growth stocks for 2022 here
.

When is Histogen's next earnings date?

Histogen is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Histogen
.

How were Histogen's earnings last quarter?

Histogen Inc. (NASDAQ:HSTO) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($1.80) EPS for the quarter, beating analysts' consensus estimates of ($2.20) by $0.40. The company earned $0.59 million during the quarter. Histogen had a negative net margin of 260.63% and a negative trailing twelve-month return on equity of 54.01%. During the same quarter last year, the business posted ($5.40) EPS.
View Histogen's earnings history
.

When did Histogen's stock split? How did Histogen's stock split work?

Shares of Histogen reverse split on Friday, June 3rd 2022. The 1-20 reverse split was announced on Friday, June 3rd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 3rd 2022. An investor that had 100 shares of Histogen stock prior to the reverse split would have 5 shares after the split.

Who are Histogen's key executives?

Histogen's management team includes the following people:
  • Dr. Steven J. Mento Ph.D., Exec. Chairman, Interim Pres & CEO (Age 70, Pay $335.4k)
  • Ms. Susan A. Knudson, Exec. VP, CFO, Chief Compliance Officer & Corp. Sec. (Age 58, Pay $385.25k)
  • Dr. Gail K. Naughton Ph.D., Founder & Scientific Advisor (Age 66)
  • Mr. Stephen Hill Jr., VP & Controller
  • Mr. Thomas L. Hubka, Director of Bus. Operations & Corp. Sec. (Age 35)

What other stocks do shareholders of Histogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Histogen investors own include Carnival Co. & (CCL), Intel (INTC), Genius Brands International (GNUS), Gilead Sciences (GILD), Clovis Oncology (CLVS), B2Gold (BTG), BIOLASE (BIOL), (BBI.V) (BBI), Advanced Micro Devices (AMD) and Akers Biosciences (AKER).

What is Histogen's stock symbol?

Histogen trades on the NASDAQ under the ticker symbol "HSTO."

Who are Histogen's major shareholders?

Histogen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.34%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends for Histogen
.

Which institutional investors are buying Histogen stock?

HSTO stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Histogen
or or view top insider-buying stocks.

How do I buy shares of Histogen?

Shares of HSTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Histogen's stock price today?

One share of HSTO stock can currently be purchased for approximately $2.33.

How much money does Histogen make?

Histogen (NASDAQ:HSTO) has a market capitalization of $5.82 million and generates $1.03 million in revenue each year. The company earns $-14.95 million in net income (profit) each year or ($5.400010) on an earnings per share basis.

How many employees does Histogen have?

Histogen employs 22 workers across the globe.

How can I contact Histogen?

Histogen's mailing address is 16745 W. Bernardo Dr. Suite 250, San Diego CA, 92127. The official website for Histogen is www.histogen.com. The company can be reached via phone at (858) 526-3100 or via email at [email protected].

This page (NASDAQ:HSTO) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.